TG Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, TGTX, TG Therapeutics Inc, priceseries

TG Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
8.88
Close
8.67
High
9.14
Low
8.49
Previous Close
8.77
Daily Price Gain
-0.10
YTD High
20.69
YTD High Date
Jan 3, 2022
YTD Low
8.04
YTD Low Date
Jan 27, 2022
YTD Price Change
-11.78
YTD Gain
-57.60%
52 Week High
51.30
52 Week High Date
Mar 22, 2021
52 Week Low
8.04
52 Week Low Date
Jan 27, 2022
52 Week Price Change
-33.04
52 Week Gain
-79.21%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 22. 2017
5.15
Mar 3. 2017
5.47
7 Trading Days
6.14%
Link
LONG
Jul 12. 2017
10.60
Jul 25. 2017
11.43
9 Trading Days
7.78%
Link
LONG
Jan 9. 2018
8.85
Jan 18. 2018
9.42
6 Trading Days
6.41%
Link
LONG
Feb 20. 2018
12.60
Mar 19. 2018
16.06
19 Trading Days
27.44%
Link
LONG
Dec 31. 2018
4.10
Jan 14. 2019
4.63
9 Trading Days
12.98%
Link
LONG
Feb 8. 2019
4.22
Mar 22. 2019
6.88
29 Trading Days
62.97%
Link
LONG
Mar 28. 2019
7.46
Apr 9. 2019
8.08
8 Trading Days
8.37%
Link
LONG
Oct 22. 2019
5.56
Nov 22. 2019
7.77
23 Trading Days
39.75%
Link
LONG
Dec 12. 2019
9.39
Jan 23. 2020
12.95
27 Trading Days
37.87%
Link
LONG
Apr 16. 2020
10.46
Apr 28. 2020
12.16
8 Trading Days
16.22%
Link
LONG
May 4. 2020
12.46
May 19. 2020
18.83
11 Trading Days
51.10%
Link
LONG
Jun 30. 2020
19.48
Jul 13. 2020
21.32
8 Trading Days
9.44%
Link
LONG
Aug 13. 2020
20.38
Sep 4. 2020
24.26
16 Trading Days
19.05%
Link
LONG
Sep 28. 2020
25.53
Oct 14. 2020
29.40
12 Trading Days
15.16%
Link
LONG
Dec 10. 2020
41.72
Jan 4. 2021
51.43
15 Trading Days
23.27%
Link
LONG
Aug 20. 2021
24.00
Oct 4. 2021
32.72
30 Trading Days
36.32%
Link
Company Information
Stock Symbol
TGTX
Exchange
NasdaqCM
Company URL
http://www.tgtherapeutics.com
Company Phone
(212) 554-4484
CEO
Michael Sean Weiss
Headquarters
New York
Business Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001001316
About

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Description

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading